Identification

Name
Pseudoephedrine
Accession Number
DB00852  (APRD00634)
Type
Small Molecule
Groups
Approved
Description

An alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used in the treatment of several disorders including asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.

Structure
Thumb
Synonyms
  • (+) threo-2-(methylamino)-1-phenyl-1-propanol
  • (+)-(1S,2S)-Pseudoephedrine
  • (+)-Pseudoephedrine
  • (+)-psi-Ephedrine
  • (+)-threo-Ephedrine
  • d-Isoephedrine
  • d-Pseudoephedrine
  • d-psi-2-Methylamino-1-phenyl-1-propanol
  • d-psi-Ephedrine
  • Isoephedrine
  • L-(+)-Pseudoephedrine
  • L(+)-psi-Ephedrine
  • Pseudoefedrina
  • pseudoéphédrine
  • Pseudoephedrine D-form
  • Pseudoephedrinum
  • Psi-ephedrin
  • Psi-ephedrine
  • trans-Ephedrine
  • ψ-ephedrine
Product Ingredients
IngredientUNIICASInChI Key
Pseudoephedrine hydrochloride6V9V2RYJ8N345-78-8BALXUFOVQVENIU-KXNXZCPBSA-N
Pseudoephedrine sulfateY9DL7QPE6B7460-12-0XVPDSDYVNYOVMP-KXNXZCPBSA-N
Product Images
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
12 Hour DecongestantTablet, film coated, extended release120 mg/1OralL. Perrigo Company2011-10-04Not applicableUs
12 Hour DecongestantTablet, film coated, extended release120 mg/1OralMeijer Distribution1999-11-05Not applicableUs
12 Hour DecongestantTablet, film coated, extended release120 mg/1OralKroger1999-12-14Not applicableUs
12 Hour Nasal DecongestantTablet, film coated, extended release120 mg/1OralCVS Health1999-12-01Not applicableUs
12 Hour Nasal Decongestant Non DrowsyTablet, film coated, extended release120 mg/1OralSafeway2000-05-252017-12-22Us
Balminil Decongestionnant Sirop 30mg/5mlSyrup30 mgOralRougier Pharma Division Of Ratiopharm Inc1988-12-312000-09-07Canada
Benylin D for InfantsSyrup7.5 mgOralPfizer Canada Inc., Consumer Healthcare Division2004-08-092006-08-03Canada
Care One Suphedrine Nasal Decongestant Non DrowsyTablet, film coated30 mg/1OralAmerican Sales Company2003-12-01Not applicableUs
CareOne Nasal and Sinus DecongestantTablet, film coated30 mg/1OralAmerican Sales Company2017-09-25Not applicableUs
CareOne Nasal and Sinus DecongestantTablet, film coated, extended release120 mg/1OralAmerican Sales Company2016-09-15Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
12 Hour Allergy and CongestionPseudoephedrine sulfate (120 mg/1) + Loratadine (5 mg/1)Tablet, film coated, extended releaseOralWalgreen2018-05-05Not applicableUs
12 Hour Allergy DPseudoephedrine hydrochloride (120 mg/1) + Cetirizine hydrochloride (5 mg/1)Tablet, extended releaseOralMeijer Distribution1988-07-15Not applicableUs
A.M. Cold Relief FormulaPseudoephedrine hydrochloride (30.0 mg) + Acetaminophen (325.0 mg) + Dextromethorphan hydrobromide (15.0 mg)CapsuleOralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Abanatuss PedPseudoephedrine hydrochloride (60 mg/5mL) + Chlophedianol hydrochloride (25 mg/5mL) + Dexchlorpheniramine maleate (2 mg/5mL)SolutionOralKramer Novis.2015-07-01Not applicableUs
Abanatuss Ped DropsPseudoephedrine hydrochloride (15 mg/mL) + Chlophedianol hydrochloride (6.25 mg/mL) + Dexchlorpheniramine maleate (.5 mg/mL)SolutionOralKramer Novis.2015-08-05Not applicableUs
Abatuss DmxPseudoephedrine hydrochloride (30 mg/5mL) + Dexchlorpheniramine maleate (1 mg/5mL) + Dextromethorphan hydrobromide (15 mg/5mL)LiquidOralKramer Novis.2014-05-25Not applicableUs
Acetaminophen/dextromethorphan/pseudoephedrinePseudoephedrine hydrochloride (30 mg) + Acetaminophen (325 mg) + Dextromethorphan hydrobromide (15 mg)CapsuleOralApotex CorporationNot applicableNot applicableCanada
Acetaminophen/pseudoephedrine/dextromethorphan/doxylaminePseudoephedrine hydrochloride (30 mg) + Acetaminophen (325 mg) + Dextromethorphan hydrobromide (15 mg) + Doxylamine succinate (6.25 mg)CapsuleOralApotex CorporationNot applicableNot applicableCanada
ActiconPseudoephedrine hydrochloride (60 mg/1) + Dexbrompheniramine maleate (2 mg/1)TabletOralActipharma, Inc2015-08-13Not applicableUs
ActiconPseudoephedrine hydrochloride (30 mg/5mL) + Dexbrompheniramine maleate (1 mg/5mL)LiquidOralActipharma, Inc2016-07-14Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Atuss DS Tannate SuspensionPseudoephedrine hydrochloride (30 mg/5mL) + Chlorpheniramine maleate (4 mg/5mL) + Dextromethorphan hydrobromide (30 mg/5mL)SuspensionOralAtley Pharmaceuticals2006-11-212017-08-29Us
DryMaxPseudoephedrine hydrochloride (30 mg/5mL) + Chlorpheniramine maleate (4 mg/5mL) + Methscopolamine nitrate (1.25 mg/5mL)SyrupOralJay Mac Pharmaceuticals2010-01-182016-10-13Us
Guaifenesin DACPseudoephedrine hydrochloride (30 mg/5mL) + Codeine phosphate (10 mg/5mL) + Guaifenesin (100 mg/5mL)LiquidOralRising Pharmaceuticals2009-09-28Not applicableUs
J-cof DhcPseudoephedrine hydrochloride (15 mg/5mL) + Brompheniramine maleate (3 mg/5mL) + Dihydrocodeine bitartrate (7.5 mg/5mL)LiquidOralJay Mac Pharmaceuticals2008-06-302016-10-13Us
Notuss-NXDPseudoephedrine hydrochloride (30 mg/5mL) + Chlorcyclizine Hydrochloride (9.375 mg/5mL) + Codeine phosphate (10 mg/5mL)LiquidOralSj Pharmaceuticals, Llc2010-11-032017-09-28Us
International/Other Brands
Afrinol / Benylin Decongestant / Cenafed / Decofed / Dimetapp Decongestant / Eltor 120 / Genaphed / Maxenal / Myfedrine / Novafed / Robidrine / Sudafed Decongestant
Categories
UNII
7CUC9DDI9F
CAS number
90-82-4
Weight
Average: 165.2322
Monoisotopic: 165.115364107
Chemical Formula
C10H15NO
InChI Key
KWGRBVOPPLSCSI-WCBMZHEXSA-N
InChI
InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1
IUPAC Name
(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol
SMILES
CN[C@@H](C)[C@@H](O)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of nasal congestion, sinus congestion, Eustachian tube congestion, and vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis. Also used as first-line therapy of priapism.

Associated Conditions
Pharmacodynamics

Pseudoephedrine is a sympathomimetic agent, structurally similar to ephedrine, used to relieve nasal and sinus congestion and reduce air-travel-related otalgia in adults. The salts pseudoephedrine hydrochloride and pseudoephedrine sulfate are found in many over-the-counter preparations either as single-ingredient preparations, or more commonly in combination with antihistamines and/or paracetamol/ibuprofen. Unlike antihistamines, which modify the systemic histamine-mediated allergic response, pseudoephedrine only serves to relieve nasal congestion commonly associated with colds or allergies. The advantage of oral pseudoephedrine over topical nasal preparations, such as oxymetazoline, is that it does not cause rebound congestion (rhinitis medicamentosa).

Mechanism of action

Pseudoephedrine acts directly on both alpha- and, to a lesser degree, beta-adrenergic receptors. Through direct action on alpha-adrenergic receptors in the mucosa of the respiratory tract, pseudoephedrine produces vasoconstriction. Pseudoephedrine relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors. Like ephedrine, pseudoephedrine releasing norepinephrine from its storage sites, an indirect effect. This is its main and direct mechanism of action. The displaced noradrenaline is released into the neuronal synapse where it is free to activate the postsynaptic adrenergic receptors.

TargetActionsOrganism
ASodium-dependent noradrenaline transporter
inhibitor
Human
ASodium-dependent dopamine transporter
inhibitor
Human
AAlpha-1A adrenergic receptor
agonist
Human
AAlpha-2A adrenergic receptor
agonist
Human
ASodium-dependent serotonin transporter
inhibitor
Human
UBeta-2 adrenergic receptor
partial agonist
Human
UBeta-1 adrenergic receptor
agonist
partial agonist
Human
UNuclear factor of activated T-cells, cytoplasmic 1
inhibitor
Human
UTumor necrosis factor
inhibitor
Human
UNuclear factor kappa-light-chain-enhancer of activated B cells
inhibitor
Human
Uactivator protein 1
inhibitor
Human
UInterleukin-2
inhibitor
Human
Absorption

Pseudoephedrine is readily and almost completely absorbed from the GI tract and there is no evidence of first-pass metabolism.

Volume of distribution
Not Available
Protein binding

Pseudoephedrine does not bind to human plasma proteins over the concentration range of 50 to 2000 ng/mL

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

9-16 hours

Clearance
Not Available
Toxicity

Common adverse reactions include nervousness, restlessness, and insomnia. Rare adverse reactions include difficult/painful urination, dizziness/lightheadedness, heart palpitations, headache, increased sweating, nausea/vomiting, trembling, troubled breathing, unusual paleness, and weakness.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Pseudoephedrine.Experimental
3-isobutyl-1-methyl-7H-xanthineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 3-isobutyl-1-methyl-7H-xanthine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Pseudoephedrine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Pseudoephedrine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Pseudoephedrine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when 5-methoxy-N,N-dimethyltryptamine is combined with Pseudoephedrine.Experimental, Illicit
6-O-benzylguanineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 6-O-benzylguanine.Investigational
7-DeazaguanineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 7-Deazaguanine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Pseudoephedrine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Pseudoephedrine.Experimental
7,9-DimethylguanineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 7,9-Dimethylguanine.Experimental
8-azaguanineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 8-azaguanine.Experimental
8-chlorotheophyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 8-chlorotheophylline.Approved
9-DeazaguanineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 9-Deazaguanine.Experimental
9-MethylguanineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with 9-Methylguanine.Experimental
AcebutololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Acebutolol.Approved, Investigational
AcefyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Acefylline.Experimental
AcepromazineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Acepromazine.Approved, Vet Approved
AceprometazinePseudoephedrine may decrease the sedative and stimulatory activities of Aceprometazine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Acetylglycinamide chloral hydrate is combined with Pseudoephedrine.Experimental
AcrivastinePseudoephedrine may decrease the sedative and stimulatory activities of Acrivastine.Approved
AcyclovirThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Acyclovir.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Adinazolam is combined with Pseudoephedrine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Pseudoephedrine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pseudoephedrine.Approved, Investigational
Ajulemic acidThe risk or severity of Tachycardia can be increased when Ajulemic acid is combined with Pseudoephedrine.Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Alaproclate.Experimental
AlcaftadinePseudoephedrine may decrease the sedative and stimulatory activities of Alcaftadine.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Pseudoephedrine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Pseudoephedrine.Vet Approved
AlfentanilPseudoephedrine may increase the analgesic activities of Alfentanil.Approved, Illicit
AlfuzosinThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Alfuzosin.Approved, Investigational
AlimemazinePseudoephedrine may decrease the sedative and stimulatory activities of Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Allobarbital is combined with Pseudoephedrine.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Pseudoephedrine.Investigational
AlmasilateAlmasilate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved, Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Pseudoephedrine.Approved, Investigational
AloglutamolAloglutamol may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Pseudoephedrine.Approved, Withdrawn
AlphacetylmethadolPseudoephedrine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodinePseudoephedrine may increase the analgesic activities of Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pseudoephedrine.Approved, Illicit, Investigational
AlprenololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Alprenolol.Approved, Withdrawn
AluminiumAluminium may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Experimental
Aluminium phosphateAluminium phosphate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved, Investigational
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved, Investigational
AlverineThe risk or severity of adverse effects can be increased when Alverine is combined with Pseudoephedrine.Approved, Investigational
AmineptineAmineptine may increase the vasopressor activities of Pseudoephedrine.Illicit, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the vasopressor activities of Pseudoephedrine.Approved
AmitriptylinoxideAmitriptylinoxide may increase the vasopressor activities of Pseudoephedrine.Approved, Investigational
Ammonium chlorideThe serum concentration of Pseudoephedrine can be decreased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pseudoephedrine.Approved, Illicit
AmoxapineAmoxapine may increase the vasopressor activities of Pseudoephedrine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Pseudoephedrine.Approved, Illicit, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Aniracetam is combined with Pseudoephedrine.Experimental
AnisodamineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Anisodamine.Investigational
AntazolinePseudoephedrine may decrease the sedative and stimulatory activities of Antazoline.Approved
APD791The risk or severity of adverse effects can be increased when APD791 is combined with Pseudoephedrine.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Pseudoephedrine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Apramycin is combined with Pseudoephedrine.Experimental, Vet Approved
AprobarbitalThe risk or severity of adverse effects can be increased when Aprobarbital is combined with Pseudoephedrine.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Apronalide is combined with Pseudoephedrine.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Arbaclofen Placarbil is combined with Pseudoephedrine.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Arbekacin is combined with Pseudoephedrine.Approved, Investigational
AripiprazolePseudoephedrine may decrease the sedative and stimulatory activities of Aripiprazole.Approved, Investigational
Aripiprazole lauroxilPseudoephedrine may decrease the sedative and stimulatory activities of Aripiprazole lauroxil.Approved, Investigational
ArotinololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Arotinolol.Investigational
Ascorbic acidThe serum concentration of Pseudoephedrine can be decreased when it is combined with Ascorbic acid.Approved, Nutraceutical
AsenapinePseudoephedrine may decrease the sedative and stimulatory activities of Asenapine.Approved
AstemizolePseudoephedrine may decrease the sedative and stimulatory activities of Astemizole.Approved, Withdrawn
AtenololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Atenolol.Approved
AtomoxetineThe risk or severity of hypertension can be increased when Atomoxetine is combined with Pseudoephedrine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Pseudoephedrine.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pseudoephedrine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Azaperone.Investigational, Vet Approved
AzatadinePseudoephedrine may decrease the sedative and stimulatory activities of Azatadine.Approved
AzathioprineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Azathioprine.Approved
AZD-3043The risk or severity of adverse effects can be increased when AZD-3043 is combined with Pseudoephedrine.Investigational
AzelastinePseudoephedrine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Pseudoephedrine.Approved
BamifyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Bamifylline.Experimental
BamipinePseudoephedrine may decrease the sedative and stimulatory activities of Bamipine.Experimental
BarbexacloneThe risk or severity of adverse effects can be increased when Barbexaclone is combined with Pseudoephedrine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Pseudoephedrine.Illicit
BeclamideThe risk or severity of adverse effects can be increased when Beclamide is combined with Pseudoephedrine.Experimental
BefunololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Befunolol.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Bekanamycin is combined with Pseudoephedrine.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Pseudoephedrine.Withdrawn
BenmoxinBenmoxin may increase the hypertensive activities of Pseudoephedrine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Benperidol.Approved, Investigational
BenzatropinePseudoephedrine may decrease the sedative and stimulatory activities of Benzatropine.Approved
BenzoctamineThe risk or severity of adverse effects can be increased when Benzoctamine is combined with Pseudoephedrine.Approved
BenzphetamineThe risk or severity of serotonin syndrome can be increased when Benzphetamine is combined with Pseudoephedrine.Approved, Illicit
BenzquinamidePseudoephedrine may decrease the sedative and stimulatory activities of Benzquinamide.Withdrawn
Benzylpenicilloyl PolylysinePseudoephedrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepotastinePseudoephedrine may decrease the sedative and stimulatory activities of Bepotastine.Approved
BetahistinePseudoephedrine may decrease the sedative and stimulatory activities of Betahistine.Approved, Investigational
BetaxololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Betaxolol.Approved, Investigational
BevantololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Bevantolol.Approved
BezitramidePseudoephedrine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifemelaneThe risk or severity of adverse effects can be increased when Bifemelane is combined with Pseudoephedrine.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Bifeprunox.Investigational
BilastinePseudoephedrine may decrease the sedative and stimulatory activities of Bilastine.Approved, Investigational
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
BisoprololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Bisoprolol.Approved
BL-1020The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Blonanserin.Approved, Investigational
BopindololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Bopindolol.Approved
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Pseudoephedrine.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pseudoephedrine.Approved, Investigational
BrexpiprazoleThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pseudoephedrine.Approved
BrinzolamideBrinzolamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Brivaracetam is combined with Pseudoephedrine.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Pseudoephedrine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pseudoephedrine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Pseudoephedrine.Experimental
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Approved, Investigational
BromodiphenhydraminePseudoephedrine may decrease the sedative and stimulatory activities of Bromodiphenhydramine.Approved
BromotheophyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Bromotheophylline.Approved
BromperidolThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Bromperidol.Approved, Investigational
BrompheniraminePseudoephedrine may decrease the sedative and stimulatory activities of Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Pseudoephedrine.Approved, Investigational, Withdrawn
BucindololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Bucindolol.Investigational
BuclizinePseudoephedrine may decrease the sedative and stimulatory activities of Buclizine.Approved
BufotenineThe risk or severity of adverse effects can be increased when Bufotenine is combined with Pseudoephedrine.Experimental, Illicit
BufuralolThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Bufuralol.Experimental, Investigational
BufyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Bufylline.Experimental
BunazosinThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Bunazosin.Investigational
BupranololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Bupranolol.Approved
BuprenorphinePseudoephedrine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Pseudoephedrine.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pseudoephedrine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pseudoephedrine.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Pseudoephedrine.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Pseudoephedrine.Approved, Illicit
ButorphanolPseudoephedrine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
ButriptylineButriptyline may increase the vasopressor activities of Pseudoephedrine.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Approved
CafedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Cafedrine.Investigational
CaffeineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Caffeine.Approved
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved, Investigational
Calcium silicateCalcium silicate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Experimental
CamazepamThe risk or severity of adverse effects can be increased when Camazepam is combined with Pseudoephedrine.Approved, Illicit
CannabidiolThe risk or severity of adverse effects can be increased when Cannabidiol is combined with Pseudoephedrine.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Cannabidivarin is combined with Pseudoephedrine.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Capreomycin is combined with Pseudoephedrine.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Captodiame is combined with Pseudoephedrine.Approved, Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pseudoephedrine.Approved, Investigational
CarbinoxaminePseudoephedrine may decrease the sedative and stimulatory activities of Carbinoxamine.Approved
CarbromalThe risk or severity of adverse effects can be increased when Carbromal is combined with Pseudoephedrine.Experimental
CarfentanilPseudoephedrine may increase the analgesic activities of Carfentanil.Illicit, Investigational, Vet Approved
CariprazinePseudoephedrine may decrease the sedative and stimulatory activities of Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Carisbamate is combined with Pseudoephedrine.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pseudoephedrine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Pseudoephedrine.Withdrawn
CarteololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Carteolol.Approved
CarvedilolThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Carvedilol.Approved, Investigational
CathinoneThe risk or severity of adverse effects can be increased when Cathinone is combined with Pseudoephedrine.Illicit
CeliprololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Celiprolol.Approved, Investigational
CerlapirdineThe risk or severity of adverse effects can be increased when Cerlapirdine is combined with Pseudoephedrine.Investigational
CetirizinePseudoephedrine may decrease the sedative and stimulatory activities of Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pseudoephedrine.Approved, Illicit, Investigational, Vet Approved
ChlorcyclizinePseudoephedrine may decrease the sedative and stimulatory activities of Chlorcyclizine.Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pseudoephedrine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Pseudoephedrine.Approved, Investigational, Withdrawn
ChloropyraminePseudoephedrine may decrease the sedative and stimulatory activities of Chloropyramine.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Pseudoephedrine.Approved, Investigational, Vet Approved
ChlorphenaminePseudoephedrine may decrease the sedative and stimulatory activities of Chlorphenamine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Chlorphenesin is combined with Pseudoephedrine.Approved, Vet Approved, Withdrawn
ChlorphenoxaminePseudoephedrine may decrease the sedative and stimulatory activities of Chlorphenoxamine.Withdrawn
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Pseudoephedrine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Chlorproethazine.Experimental
ChlorpromazinePseudoephedrine may decrease the sedative and stimulatory activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixenePseudoephedrine may decrease the sedative and stimulatory activities of Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Chlortetracycline is combined with Pseudoephedrine.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pseudoephedrine.Approved
CilansetronThe risk or severity of adverse effects can be increased when Cilansetron is combined with Pseudoephedrine.Investigational
CimetidinePseudoephedrine may decrease the sedative and stimulatory activities of Cimetidine.Approved, Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Cinitapride is combined with Pseudoephedrine.Approved, Investigational
CinnarizinePseudoephedrine may decrease the sedative and stimulatory activities of Cinnarizine.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Cinolazepam is combined with Pseudoephedrine.Approved
CisaprideThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Cisatracurium is combined with Pseudoephedrine.Approved
CitalopramThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Citalopram.Approved
ClemastinePseudoephedrine may decrease the sedative and stimulatory activities of Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Pseudoephedrine.Approved, Investigational, Vet Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Pseudoephedrine.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Pseudoephedrine.Approved, Illicit
ClofedanolPseudoephedrine may decrease the sedative and stimulatory activities of Clofedanol.Approved, Withdrawn
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Pseudoephedrine.Investigational
ClomipramineClomipramine may increase the vasopressor activities of Pseudoephedrine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Clomocycline is combined with Pseudoephedrine.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Pseudoephedrine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Pseudoephedrine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Clopenthixol.Experimental
CloranololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pseudoephedrine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Clotiazepam is combined with Pseudoephedrine.Approved, Illicit
CloxazolamThe risk or severity of adverse effects can be increased when Cloxazolam is combined with Pseudoephedrine.Approved, Investigational
ClozapinePseudoephedrine may decrease the sedative and stimulatory activities of Clozapine.Approved
CodeinePseudoephedrine may increase the analgesic activities of Codeine.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Colistimethate is combined with Pseudoephedrine.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Colistin is combined with Pseudoephedrine.Approved
CP-945598The risk or severity of Tachycardia can be increased when CP-945598 is combined with Pseudoephedrine.Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Cyamemazine.Approved
CyclizinePseudoephedrine may decrease the sedative and stimulatory activities of Cyclizine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Cyclobarbital is combined with Pseudoephedrine.Experimental
CyclobenzaprineCyclobenzaprine may increase the vasopressor activities of Pseudoephedrine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Pseudoephedrine.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pseudoephedrine.Approved, Investigational, Vet Approved
CyproheptadinePseudoephedrine may decrease the sedative and stimulatory activities of Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pseudoephedrine.Approved, Investigational
DapiprazoleThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Dapoxetine.Investigational
DeanolThe risk or severity of adverse effects can be increased when Deanol is combined with Pseudoephedrine.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Decamethonium is combined with Pseudoephedrine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Delorazepam is combined with Pseudoephedrine.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Demeclocycline is combined with Pseudoephedrine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Pseudoephedrine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Pseudoephedrine.Approved
DesipramineDesipramine may increase the vasopressor activities of Pseudoephedrine.Approved, Investigational
DesloratadinePseudoephedrine may decrease the sedative and stimulatory activities of Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Pseudoephedrine.Vet Approved
DexbrompheniraminePseudoephedrine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Approved
DexchlorpheniraminePseudoephedrine may decrease the sedative and stimulatory activities of Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleatePseudoephedrine may decrease the sedative and stimulatory activities of Dexchlorpheniramine maleate.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pseudoephedrine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Pseudoephedrine.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Dextofisopam is combined with Pseudoephedrine.Investigational
DextroamphetamineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Pseudoephedrine.Approved
DextromoramidePseudoephedrine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxyphenePseudoephedrine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocinePseudoephedrine may increase the analgesic activities of Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Pseudoephedrine.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Dibekacin is combined with Pseudoephedrine.Experimental
DibenzepinDibenzepin may increase the vasopressor activities of Pseudoephedrine.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Pseudoephedrine.Approved, Illicit
DiclofenamideDiclofenamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved, Investigational
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Pseudoephedrine.Experimental
DiethylpropionThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Pseudoephedrine.Approved, Illicit
DihydrocodeinePseudoephedrine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroergocornineDihydroergocornine may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Approved
DihydroergocristineDihydroergocristine may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Approved, Experimental
DihydroergocryptineDihydroergocryptine may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Experimental
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Approved, Investigational
DihydroetorphinePseudoephedrine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphinePseudoephedrine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Pseudoephedrine.Investigational, Vet Approved
DimenhydrinatePseudoephedrine may decrease the sedative and stimulatory activities of Dimenhydrinate.Approved
DimetacrineDimetacrine may increase the vasopressor activities of Pseudoephedrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Pseudoephedrine.Experimental, Illicit
DimetindenePseudoephedrine may decrease the sedative and stimulatory activities of Dimetindene.Approved, Investigational
DimetotiazinePseudoephedrine may decrease the sedative and stimulatory activities of Dimetotiazine.Approved
DiphenhydraminePseudoephedrine may decrease the sedative and stimulatory activities of Diphenhydramine.Approved, Investigational
DiphenoxylatePseudoephedrine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DiphenylpyralinePseudoephedrine may decrease the sedative and stimulatory activities of Diphenylpyraline.Approved, Investigational
DixyrazineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Dixyrazine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Pseudoephedrine.Approved
DolasetronThe risk or severity of adverse effects can be increased when Dolasetron is combined with Pseudoephedrine.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Domoic Acid is combined with Pseudoephedrine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Donepezil is combined with Pseudoephedrine.Approved
DopamineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Pseudoephedrine.Vet Approved
DorzolamideDorzolamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
DosulepinDosulepin may increase the vasopressor activities of Pseudoephedrine.Approved
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Pseudoephedrine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Doxacurium is combined with Pseudoephedrine.Approved
DoxazosinThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Doxazosin.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Doxefazepam is combined with Pseudoephedrine.Experimental
DoxepinDoxepin may increase the vasopressor activities of Pseudoephedrine.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Doxofylline.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Pseudoephedrine.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pseudoephedrine.Approved, Vet Approved
DPDPEPseudoephedrine may increase the analgesic activities of DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pseudoephedrine.Approved, Illicit
DronedaroneThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pseudoephedrine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Pseudoephedrine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pseudoephedrine.Approved
EbastinePseudoephedrine may decrease the sedative and stimulatory activities of Ebastine.Approved, Investigational
EcopipamThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Edivoxetine is combined with Pseudoephedrine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Pseudoephedrine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Pseudoephedrine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Pseudoephedrine.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Eltoprazine is combined with Pseudoephedrine.Investigational
EluxadolinePseudoephedrine may increase the analgesic activities of Eluxadoline.Approved, Investigational
EmedastinePseudoephedrine may decrease the sedative and stimulatory activities of Emedastine.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Pseudoephedrine.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Emylcamate is combined with Pseudoephedrine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pseudoephedrine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Pseudoephedrine.Approved, Investigational
EntecavirThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Entecavir.Approved, Investigational
EpanololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Epanolol.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Pseudoephedrine.Approved, Investigational
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Pseudoephedrine.Approved
EpinastinePseudoephedrine may decrease the sedative and stimulatory activities of Epinastine.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Pseudoephedrine.Approved, Vet Approved
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Pseudoephedrine.Investigational
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Approved
EsatenololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Esatenolol.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Pseudoephedrine.Approved
EsmirtazapinePseudoephedrine may decrease the sedative and stimulatory activities of Esmirtazapine.Investigational
EsmololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Esmolol.Approved
EsreboxetineThe risk or severity of adverse effects can be increased when Esreboxetine is combined with Pseudoephedrine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Pseudoephedrine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pseudoephedrine.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Pseudoephedrine.Approved, Investigational
EtamiphyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Etamiphylline.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Ethadione is combined with Pseudoephedrine.Experimental
EthanolPseudoephedrine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pseudoephedrine.Approved, Illicit, Withdrawn
EthosuximidePseudoephedrine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pseudoephedrine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pseudoephedrine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Pseudoephedrine.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Pseudoephedrine.Approved, Illicit
EthylmorphinePseudoephedrine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Pseudoephedrine.Investigational, Withdrawn
EtilefrineThe risk or severity of adverse effects can be increased when Etilefrine is combined with Pseudoephedrine.Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Etiracetam is combined with Pseudoephedrine.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Pseudoephedrine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Etoperidone.Withdrawn
EtorphinePseudoephedrine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Pseudoephedrine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Fabomotizole is combined with Pseudoephedrine.Experimental
FamotidinePseudoephedrine may decrease the sedative and stimulatory activities of Famotidine.Approved
Fazadinium bromideThe risk or severity of adverse effects can be increased when Fazadinium bromide is combined with Pseudoephedrine.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Febarbamate is combined with Pseudoephedrine.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Pseudoephedrine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pseudoephedrine.Approved, Illicit, Withdrawn
FenethyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Fenethylline.Approved
FenfluramineThe risk or severity of adverse effects can be increased when Fenfluramine is combined with Pseudoephedrine.Approved, Illicit, Investigational, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Pseudoephedrine.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Fenozolone is combined with Pseudoephedrine.Experimental
FentanylThe therapeutic efficacy of Fentanyl can be decreased when used in combination with Pseudoephedrine.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Fenyramidol is combined with Pseudoephedrine.Experimental
FexofenadinePseudoephedrine may decrease the sedative and stimulatory activities of Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pseudoephedrine.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pseudoephedrine.Approved, Illicit
FlunarizinePseudoephedrine may decrease the sedative and stimulatory activities of Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Pseudoephedrine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pseudoephedrine.Approved, Illicit, Investigational
FluspirileneFluspirilene may decrease the stimulatory activities of Pseudoephedrine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pseudoephedrine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Pseudoephedrine.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Pseudoephedrine.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Framycetin is combined with Pseudoephedrine.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Pseudoephedrine.Approved, Investigational
FurafyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Furafylline.Experimental
FurazolidoneFurazolidone may increase the hypertensive activities of Pseudoephedrine.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pseudoephedrine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Pseudoephedrine.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Gaboxadol is combined with Pseudoephedrine.Investigational
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Pseudoephedrine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pseudoephedrine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Pseudoephedrine.Approved, Illicit, Investigational
GanciclovirThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Ganciclovir.Approved, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Gantacurium Chloride is combined with Pseudoephedrine.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Gedocarnil is combined with Pseudoephedrine.Experimental
GeneticinThe risk or severity of adverse effects can be increased when Geneticin is combined with Pseudoephedrine.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Gentamicin is combined with Pseudoephedrine.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when GENTAMICIN C1A is combined with Pseudoephedrine.Experimental
GepefrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Pseudoephedrine.Investigational
Glutamic AcidThe serum concentration of Pseudoephedrine can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Pseudoephedrine.Approved, Illicit
GranisetronThe risk or severity of adverse effects can be increased when Granisetron is combined with Pseudoephedrine.Approved, Investigational
GSK-1004723Pseudoephedrine may decrease the sedative and stimulatory activities of GSK-1004723.Investigational
GuanethidineThe serum concentration of Pseudoephedrine can be decreased when it is combined with Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pseudoephedrine.Approved, Investigational
GuanineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Guanine.Experimental
GW842166The risk or severity of Tachycardia can be increased when GW842166 is combined with Pseudoephedrine.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Pseudoephedrine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Pseudoephedrine.Approved, Vet Approved
HarmalineHarmaline may increase the hypertensive activities of Pseudoephedrine.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Heptabarbital is combined with Pseudoephedrine.Approved
HeroinPseudoephedrine may increase the analgesic activities of Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Hexafluronium is combined with Pseudoephedrine.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Pseudoephedrine.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Hexapropymate is combined with Pseudoephedrine.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pseudoephedrine.Approved
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Pseudoephedrine.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypertensive activities of Pseudoephedrine.Experimental
HydrocodoneThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Pseudoephedrine.Approved, Illicit
HydromorphonePseudoephedrine may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved, Experimental, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Pseudoephedrine.Approved
HydroxyzinePseudoephedrine may decrease the sedative and stimulatory activities of Hydroxyzine.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Hygromycin B is combined with Pseudoephedrine.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Pseudoephedrine.Investigational
HypoxanthineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Hypoxanthine.Experimental
IbipinabantThe risk or severity of Tachycardia can be increased when Ibipinabant is combined with Pseudoephedrine.Investigational
IdalopirdineThe risk or severity of adverse effects can be increased when Idalopirdine is combined with Pseudoephedrine.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Pseudoephedrine.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Iferanserin is combined with Pseudoephedrine.Investigational
IloperidonePseudoephedrine may decrease the sedative and stimulatory activities of Iloperidone.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Imagabalin is combined with Pseudoephedrine.Investigational
ImipramineImipramine may increase the vasopressor activities of Pseudoephedrine.Approved
Imipramine oxideImipramine oxide may increase the vasopressor activities of Pseudoephedrine.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Indalpine.Investigational, Withdrawn
IndenololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Indenolol.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Pseudoephedrine.Investigational
IndoraminThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Indoramin.Withdrawn
IobenguanePseudoephedrine can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iofetamine I-123The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Iofetamine I-123.Approved
Ioflupane I-123Pseudoephedrine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Iprazochrome is combined with Pseudoephedrine.Experimental
IprindoleIprindole may increase the vasopressor activities of Pseudoephedrine.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Pseudoephedrine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Pseudoephedrine.Withdrawn
IsepamicinThe risk or severity of adverse effects can be increased when Isepamicin is combined with Pseudoephedrine.Experimental
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Pseudoephedrine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Pseudoephedrine.Approved, Vet Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Pseudoephedrine.Approved, Investigational
IsothipendylPseudoephedrine may decrease the sedative and stimulatory activities of Isothipendyl.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Pseudoephedrine.Approved, Withdrawn
KanamycinThe risk or severity of adverse effects can be increased when Kanamycin is combined with Pseudoephedrine.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pseudoephedrine.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Pseudoephedrine.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pseudoephedrine.Approved
KetobemidonePseudoephedrine may increase the analgesic activities of Ketobemidone.Approved, Investigational
KetotifenPseudoephedrine may decrease the sedative and stimulatory activities of Ketotifen.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pseudoephedrine.Approved, Nutraceutical, Withdrawn
LabetalolThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Labetalol.Approved
LacosamideThe risk or severity of adverse effects can be increased when Lacosamide is combined with Pseudoephedrine.Approved
LafutidinePseudoephedrine may decrease the sedative and stimulatory activities of Lafutidine.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pseudoephedrine.Approved, Investigational
LandiololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Landiolol.Investigational
LanicemineThe risk or severity of adverse effects can be increased when Lanicemine is combined with Pseudoephedrine.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Lasmiditan is combined with Pseudoephedrine.Investigational
LavoltidinePseudoephedrine may decrease the sedative and stimulatory activities of Lavoltidine.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pseudoephedrine.Approved, Investigational
LevobetaxololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Levobetaxolol.Approved, Investigational
LevobunololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Levobunolol.Approved
LevocabastinePseudoephedrine may decrease the sedative and stimulatory activities of Levocabastine.Approved, Investigational
LevocetirizinePseudoephedrine may decrease the sedative and stimulatory activities of Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Pseudoephedrine.Approved
Levomethadyl AcetatePseudoephedrine may increase the analgesic activities of Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Levomilnacipran.Approved, Investigational
LevorphanolPseudoephedrine may increase the analgesic activities of Levorphanol.Approved
LincomycinThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of hypertension can be increased when Linezolid is combined with Pseudoephedrine.Approved, Investigational
LisdexamfetamineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Lisdexamfetamine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Lisofylline.Investigational
LisurideLisuride may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Lithium carbonate is combined with Pseudoephedrine.Approved
Lithium cationLithium cation may decrease the stimulatory activities of Pseudoephedrine.Experimental
LobucavirThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Lobucavir.Investigational
LofentanilPseudoephedrine may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may increase the vasopressor activities of Pseudoephedrine.Experimental
LofexidineThe therapeutic efficacy of Pseudoephedrine can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Pseudoephedrine.Experimental
LoratadinePseudoephedrine may decrease the sedative and stimulatory activities of Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pseudoephedrine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Pseudoephedrine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Pseudoephedrine.Approved
LorpiprazoleThe risk or severity of adverse effects can be increased when Lorpiprazole is combined with Pseudoephedrine.Approved
LortalamineThe risk or severity of adverse effects can be increased when Lortalamine is combined with Pseudoephedrine.Experimental
LoxapineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Loxapine.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Lumateperone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Lurasidone.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Lymecycline is combined with Pseudoephedrine.Approved, Investigational
Lysergic Acid DiethylamideLysergic Acid Diethylamide may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when m-Chlorophenylpiperazine is combined with Pseudoephedrine.Investigational
MagaldrateMagaldrate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved, Withdrawn
Magnesium acetateThe risk or severity of adverse effects can be increased when Magnesium acetate is combined with Pseudoephedrine.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Magnesium acetate tetrahydrate is combined with Pseudoephedrine.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Pseudoephedrine.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Magnesium aspartate is combined with Pseudoephedrine.Experimental
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Magnesium cation is combined with Pseudoephedrine.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Magnesium chloride is combined with Pseudoephedrine.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Magnesium citrate is combined with Pseudoephedrine.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Magnesium gluconate is combined with Pseudoephedrine.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Magnesium glycinate is combined with Pseudoephedrine.Approved
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Magnesium orotate is combined with Pseudoephedrine.Experimental
Magnesium oxideMagnesium oxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Experimental
Magnesium phosphateThe risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Pseudoephedrine.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Magnesium stearate is combined with Pseudoephedrine.Investigational
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
MaprotilinePseudoephedrine may decrease the sedative and stimulatory activities of Maprotiline.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Mazindol is combined with Pseudoephedrine.Approved, Investigational
MebanazineMebanazine may increase the hypertensive activities of Pseudoephedrine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Pseudoephedrine.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Mebutamate is combined with Pseudoephedrine.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pseudoephedrine.Approved, Investigational
MeclizinePseudoephedrine may decrease the sedative and stimulatory activities of Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Pseudoephedrine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Pseudoephedrine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Medifoxamine is combined with Pseudoephedrine.Experimental
MefenorexThe risk or severity of adverse effects can be increased when Mefenorex is combined with Pseudoephedrine.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Pseudoephedrine.Approved, Nutraceutical, Vet Approved
MelitracenMelitracen may increase the vasopressor activities of Pseudoephedrine.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Melperone.Approved, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Mephedrone.Investigational
MephenesinThe risk or severity of adverse effects can be increased when Mephenesin is combined with Pseudoephedrine.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Mephenoxalone is combined with Pseudoephedrine.Experimental
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Pseudoephedrine.Approved
MephenytoinThe risk or severity of adverse effects can be increased when Mephenytoin is combined with Pseudoephedrine.Investigational, Withdrawn
MepindololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Mepindolol.Experimental
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pseudoephedrine.Approved, Illicit
MeptazinolPseudoephedrine may increase the analgesic activities of Meptazinol.Experimental
MepyraminePseudoephedrine may decrease the sedative and stimulatory activities of Mepyramine.Approved, Vet Approved
MequitazinePseudoephedrine may decrease the sedative and stimulatory activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Mesoridazine.Approved, Investigational
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Pseudoephedrine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pseudoephedrine.Approved
MetergolineMetergoline may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Methacycline is combined with Pseudoephedrine.Approved, Investigational
MethadonePseudoephedrine may increase the analgesic activities of Methadone.Approved
Methadyl AcetatePseudoephedrine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Pseudoephedrine.Approved, Illicit
MethanthelinePseudoephedrine may decrease the sedative and stimulatory activities of Methantheline.Approved, Investigational
MethapyrilenePseudoephedrine may decrease the sedative and stimulatory activities of Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Pseudoephedrine.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Metharbital is combined with Pseudoephedrine.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
MethdilazinePseudoephedrine may decrease the sedative and stimulatory activities of Methdilazine.Approved
MethenamineThe serum concentration of Pseudoephedrine can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pseudoephedrine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Pseudoephedrine.Approved
MethotrimeprazinePseudoephedrine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Pseudoephedrine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pseudoephedrine.Approved, Investigational, Vet Approved
MethoxyphenamineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pseudoephedrine.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Pseudoephedrine.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Approved
MethylpentynolThe risk or severity of adverse effects can be increased when Methylpentynol is combined with Pseudoephedrine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Pseudoephedrine.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pseudoephedrine.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Methyprylon is combined with Pseudoephedrine.Approved, Illicit, Withdrawn
MethysergideMethysergide may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Approved
MetiamidePseudoephedrine may decrease the sedative and stimulatory activities of Metiamide.Experimental
MetipranololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Metipranolol.Approved
MetoclopramideThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Pseudoephedrine.Approved, Investigational
MetocurineThe risk or severity of adverse effects can be increased when Metocurine is combined with Pseudoephedrine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Metocurine Iodide is combined with Pseudoephedrine.Approved, Withdrawn
MetoprololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Metoprolol.Approved, Investigational
MetyrosinePseudoephedrine may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Mianserin.Approved, Investigational
MicronomicinThe risk or severity of adverse effects can be increased when Micronomicin is combined with Pseudoephedrine.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Pseudoephedrine.Approved, Illicit
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Pseudoephedrine.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Pseudoephedrine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Pseudoephedrine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pseudoephedrine.Approved, Investigational
MirtazapinePseudoephedrine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumThe risk or severity of adverse effects can be increased when Mivacurium is combined with Pseudoephedrine.Approved
MizolastinePseudoephedrine may decrease the sedative and stimulatory activities of Mizolastine.Investigational
MK-212The risk or severity of adverse effects can be increased when MK-212 is combined with Pseudoephedrine.Investigational
MMDAThe risk or severity of adverse effects can be increased when MMDA is combined with Pseudoephedrine.Experimental, Illicit
MoclobemideMoclobemide may increase the hypertensive activities of Pseudoephedrine.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Moricizine.Approved, Investigational, Withdrawn
MorphinePseudoephedrine may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Mosapride is combined with Pseudoephedrine.Investigational
MRK-409The risk or severity of adverse effects can be increased when MRK-409 is combined with Pseudoephedrine.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Pseudoephedrine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pseudoephedrine.Approved, Investigational
NabiximolsThe risk or severity of Tachycardia can be increased when Nabiximols is combined with Pseudoephedrine.Approved, Investigational
NadololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Nadolol.Approved
NaftidrofurylThe risk or severity of adverse effects can be increased when Naftidrofuryl is combined with Pseudoephedrine.Experimental
NalbuphinePseudoephedrine may increase the analgesic activities of Nalbuphine.Approved
NaltrexonePseudoephedrine may increase the analgesic activities of Naltrexone.Approved, Investigational, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when Naluzotan is combined with Pseudoephedrine.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Pseudoephedrine.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Naronapride is combined with Pseudoephedrine.Investigational
NeamineThe risk or severity of adverse effects can be increased when Neamine is combined with Pseudoephedrine.Experimental
NebivololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Pseudoephedrine.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when Neocitrullamon is combined with Pseudoephedrine.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Neomycin is combined with Pseudoephedrine.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Neosaxitoxin is combined with Pseudoephedrine.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Netilmicin is combined with Pseudoephedrine.Approved, Investigational
NialamideNialamide may increase the hypertensive activities of Pseudoephedrine.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Niaprazine is combined with Pseudoephedrine.Experimental
NicardipineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Approved, Investigational
NicomorphinePseudoephedrine may increase the analgesic activities of Nicomorphine.Experimental
NiguldipineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Niguldipine.Experimental
NiperotidinePseudoephedrine may decrease the sedative and stimulatory activities of Niperotidine.Experimental, Investigational
NisoxetineThe risk or severity of adverse effects can be increased when Nisoxetine is combined with Pseudoephedrine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pseudoephedrine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Pseudoephedrine.Approved, Vet Approved
NizatidinePseudoephedrine may decrease the sedative and stimulatory activities of Nizatidine.Approved
NomifensineThe risk or severity of adverse effects can be increased when Nomifensine is combined with Pseudoephedrine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with Pseudoephedrine.Approved
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Pseudoephedrine.Approved
NormethadonePseudoephedrine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the vasopressor activities of Pseudoephedrine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Nylidrin is combined with Pseudoephedrine.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Pseudoephedrine.Withdrawn
OlanzapinePseudoephedrine may decrease the sedative and stimulatory activities of Olanzapine.Approved, Investigational
OlopatadinePseudoephedrine may decrease the sedative and stimulatory activities of Olopatadine.Approved
OndansetronThe risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Pseudoephedrine.Approved
OpipramolOpipramol may increase the vasopressor activities of Pseudoephedrine.Investigational
OpiumPseudoephedrine may increase the analgesic activities of Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Pseudoephedrine.Approved
OrphenadrinePseudoephedrine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Orvepitant is combined with Pseudoephedrine.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Osanetant.Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Oxaflozane is combined with Pseudoephedrine.Experimental
OxaprotilineOxaprotiline may increase the vasopressor activities of Pseudoephedrine.Experimental
OxatomidePseudoephedrine may decrease the sedative and stimulatory activities of Oxatomide.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pseudoephedrine.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Pseudoephedrine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Oxiracetam is combined with Pseudoephedrine.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Oxitriptan is combined with Pseudoephedrine.Approved, Investigational, Nutraceutical
OxprenololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Oxprenolol.Approved
OxtriphyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Oxtriphylline.Approved
OxycodonePseudoephedrine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Pseudoephedrine.Approved, Investigational
OxymorphonePseudoephedrine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Oxypertine.Experimental
OxytetracyclineThe risk or severity of adverse effects can be increased when Oxytetracycline is combined with Pseudoephedrine.Approved, Investigational, Vet Approved
PaliperidoneThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Paliperidone.Approved
PalmidrolThe risk or severity of Tachycardia can be increased when Palmidrol is combined with Pseudoephedrine.Experimental, Nutraceutical
PalonosetronThe risk or severity of adverse effects can be increased when Palonosetron is combined with Pseudoephedrine.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pseudoephedrine.Approved
ParaldehydePseudoephedrine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Paramethadione is combined with Pseudoephedrine.Approved
PargylinePargyline may increase the hypertensive activities of Pseudoephedrine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Paroxetine.Approved, Investigational
Patent BlueThe risk or severity of hypotension can be increased when Patent Blue is combined with Pseudoephedrine.Approved
PeldesineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Peldesine.Experimental, Investigational
PemetrexedThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Pemetrexed.Approved, Investigational
PenbutololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Penbutolol.Approved, Investigational
PenciclovirThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Penciclovir.Approved
PenfluridolPenfluridol may decrease the stimulatory activities of Pseudoephedrine.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Penimepicycline is combined with Pseudoephedrine.Experimental
PentazocinePseudoephedrine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PentifyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Pentifylline.Experimental
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pseudoephedrine.Approved, Investigational, Vet Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Pentoxifylline.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pseudoephedrine.Approved
PerazineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Perazine.Approved, Investigational
PergolidePergolide may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Perphenazine.Approved
PethidinePseudoephedrine may increase the analgesic activities of Pethidine.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Phenacemide is combined with Pseudoephedrine.Approved
PhenazocinePseudoephedrine may increase the analgesic activities of Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Phencyclidine is combined with Pseudoephedrine.Illicit
PhenelzinePhenelzine may increase the hypertensive activities of Pseudoephedrine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Phenethylamine is combined with Pseudoephedrine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Pheneturide is combined with Pseudoephedrine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Pseudoephedrine.Experimental
PhenindaminePseudoephedrine may decrease the sedative and stimulatory activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Pseudoephedrine.Withdrawn
PheniraminePseudoephedrine may decrease the sedative and stimulatory activities of Pheniramine.Approved
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Pseudoephedrine.Approved, Illicit
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Pseudoephedrine.Approved, Investigational
PhenoperidinePseudoephedrine may increase the analgesic activities of Phenoperidine.Experimental
PhenoxybenzamineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Pseudoephedrine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Phenprobamate is combined with Pseudoephedrine.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Phensuximide is combined with Pseudoephedrine.Approved
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Pseudoephedrine.Approved, Illicit
PhentolamineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Phentolamine.Approved
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Pseudoephedrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Pseudoephedrine.Approved, Vet Approved, Withdrawn
PhenytoinThe therapeutic efficacy of Phenytoin can be decreased when used in combination with Pseudoephedrine.Approved, Vet Approved
PiclozotanThe risk or severity of adverse effects can be increased when Piclozotan is combined with Pseudoephedrine.Investigational
PimavanserinThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Pimozide.Approved
PinazepamThe risk or severity of adverse effects can be increased when Pinazepam is combined with Pseudoephedrine.Experimental
PindololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pseudoephedrine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Pipotiazine.Approved, Investigational
PiritramidePseudoephedrine may increase the analgesic activities of Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Pirlimycin.Vet Approved
PirlindolePirlindole may increase the hypertensive activities of Pseudoephedrine.Approved
PitolisantPseudoephedrine may decrease the sedative and stimulatory activities of Pitolisant.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Pseudoephedrine.Investigational
PivhydrazinePivhydrazine may increase the hypertensive activities of Pseudoephedrine.Withdrawn
PizotifenPseudoephedrine may decrease the sedative and stimulatory activities of Pizotifen.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Plazomicin is combined with Pseudoephedrine.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Polymyxin B Sulfate is combined with Pseudoephedrine.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Pseudoephedrine.Approved
PractololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Practolol.Approved
PramipexolePseudoephedrine may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Pseudoephedrine.Approved, Illicit
PrazosinThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Prazosin.Approved
PregabalinThe therapeutic efficacy of Pseudoephedrine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolThe risk or severity of adverse effects can be increased when Prenalterol is combined with Pseudoephedrine.Experimental
PridinolThe risk or severity of adverse effects can be increased when Pridinol is combined with Pseudoephedrine.Experimental
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Pseudoephedrine.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Procainamide is combined with Pseudoephedrine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Pseudoephedrine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Pseudoephedrine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Pseudoephedrine.Approved, Investigational
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Pseudoephedrine.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Progabide is combined with Pseudoephedrine.Approved, Investigational
PromazinePseudoephedrine may decrease the sedative and stimulatory activities of Promazine.Approved, Vet Approved
PromethazinePseudoephedrine may decrease the sedative and stimulatory activities of Promethazine.Approved, Investigational
PropafenoneThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Pseudoephedrine.Experimental
PropentofyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Propentofylline.Investigational
PropericiazineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Propericiazine.Approved, Investigational
PropiomazinePseudoephedrine may decrease the sedative and stimulatory activities of Propiomazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Propiopromazine.Vet Approved
PropiverineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Pseudoephedrine.Approved, Investigational, Vet Approved
PropranololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Prothipendyl.Investigational
ProtriptylineProtriptyline may increase the vasopressor activities of Pseudoephedrine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Pseudoephedrine.Experimental
ProxyphyllineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Proxyphylline.Experimental
PRX-08066The risk or severity of adverse effects can be increased when PRX-08066 is combined with Pseudoephedrine.Investigational
PsilocybineThe risk or severity of adverse effects can be increased when Psilocybine is combined with Pseudoephedrine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Puromycin is combined with Pseudoephedrine.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Pyrantel is combined with Pseudoephedrine.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Pyrithyldione is combined with Pseudoephedrine.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Pseudoephedrine.Approved, Illicit
QuetiapinePseudoephedrine may decrease the sedative and stimulatory activities of Quetiapine.Approved
QuifenadinePseudoephedrine may decrease the sedative and stimulatory activities of Quifenadine.Experimental
QuinidineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Quinidine.Approved, Investigational
QuinineThe risk or severity of adverse effects can be increased when Quinine is combined with Pseudoephedrine.Approved
QuinupramineQuinupramine may increase the vasopressor activities of Pseudoephedrine.Experimental
RacepinephrineThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Pseudoephedrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Pseudoephedrine.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Ramosetron is combined with Pseudoephedrine.Approved, Investigational
RanitidinePseudoephedrine may decrease the sedative and stimulatory activities of Ranitidine.Approved
RapacuroniumThe risk or severity of adverse effects can be increased when Rapacuronium is combined with Pseudoephedrine.Withdrawn
RasagilineRasagiline may increase the hypertensive activities of Pseudoephedrine.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Reboxetine is combined with Pseudoephedrine.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Remacemide is combined with Pseudoephedrine.Investigational
RemifentanilPseudoephedrine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Renzapride is combined with Pseudoephedrine.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Repinotan is combined with Pseudoephedrine.Investigational
ReposalThe risk or severity of adverse effects can be increased when Reposal is combined with Pseudoephedrine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Reserpine.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Ribostamycin is combined with Pseudoephedrine.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Riluzole is combined with Pseudoephedrine.Approved, Investigational
RimonabantThe risk or severity of Tachycardia can be increased when Rimonabant is combined with Pseudoephedrine.Approved, Investigational
RisperidonePseudoephedrine may decrease the sedative and stimulatory activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Ritanserin.Investigational
RitobegronThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Pseudoephedrine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Pseudoephedrine.Approved
RocuroniumThe risk or severity of adverse effects can be increased when Rocuronium is combined with Pseudoephedrine.Approved
RolipramThe risk or severity of adverse effects can be increased when Rolipram is combined with Pseudoephedrine.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Rolitetracycline is combined with Pseudoephedrine.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Pseudoephedrine.Vet Approved
RopinirolePseudoephedrine may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotinePseudoephedrine may increase the sedative activities of Rotigotine.Approved
Roxatidine acetatePseudoephedrine may decrease the sedative and stimulatory activities of Roxatidine acetate.Approved, Investigational
RP-5063The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pseudoephedrine.Approved
RupatadinePseudoephedrine may decrease the sedative and stimulatory activities of Rupatadine.Approved
SafinamideSafinamide may increase the hypertensive activities of Pseudoephedrine.Approved, Investigational
SafrazineSafrazine may increase the hypertensive activities of Pseudoephedrine.Withdrawn
SaredutantThe risk or severity of adverse effects can be increased when Saredutant is combined with Pseudoephedrine.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Pseudoephedrine.Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pseudoephedrine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Selegiline.Approved, Investigational, Vet Approved
SerotoninThe risk or severity of adverse effects can be increased when Serotonin is combined with Pseudoephedrine.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pseudoephedrine.Approved, Vet Approved
SibutramineSibutramine may increase the tachycardic activities of Pseudoephedrine.Approved, Illicit, Investigational, Withdrawn
SilodosinThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Silodosin.Approved
SisomicinThe risk or severity of adverse effects can be increased when Sisomicin is combined with Pseudoephedrine.Investigational
SLV319The risk or severity of Tachycardia can be increased when SLV319 is combined with Pseudoephedrine.Investigational
Sodium bicarbonateSodium bicarbonate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pseudoephedrine.Approved
SotalolThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Sotalol.Approved
SpironolactoneThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Spironolactone.Approved
St. John's WortThe risk or severity of adverse effects can be increased when St. John's Wort is combined with Pseudoephedrine.Approved, Investigational, Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Pseudoephedrine.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Streptomycin is combined with Pseudoephedrine.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Styramate is combined with Pseudoephedrine.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Succinylcholine is combined with Pseudoephedrine.Approved
SufentanilPseudoephedrine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Sulthiame is combined with Pseudoephedrine.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Pseudoephedrine.Approved, Investigational
SurinabantThe risk or severity of Tachycardia can be increased when Surinabant is combined with Pseudoephedrine.Investigational
SuvorexantPseudoephedrine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrineThe risk or severity of adverse effects can be increased when Synephrine is combined with Pseudoephedrine.Experimental
TalbutalThe risk or severity of adverse effects can be increased when Talbutal is combined with Pseudoephedrine.Approved, Illicit
TalinololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Talinolol.Investigational
TalopramThe risk or severity of adverse effects can be increased when Talopram is combined with Pseudoephedrine.Experimental
TamsulosinThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Pseudoephedrine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Pseudoephedrine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Pseudoephedrine.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when TD-8954 is combined with Pseudoephedrine.Investigational
Tedizolid phosphateTedizolid phosphate may increase the serotonergic activities of Pseudoephedrine.Approved
TegaserodThe risk or severity of adverse effects can be increased when Tegaserod is combined with Pseudoephedrine.Approved, Investigational, Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pseudoephedrine.Approved, Investigational
TerazosinThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Terazosin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Pseudoephedrine.Approved
TerfenadinePseudoephedrine may decrease the sedative and stimulatory activities of Terfenadine.Approved, Withdrawn
TergurideTerguride may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Experimental
TertatololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Tertatolol.Experimental
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Tetrahydrocannabivarin is combined with Pseudoephedrine.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of Pseudoephedrine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Tetrazepam is combined with Pseudoephedrine.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Pseudoephedrine.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Pseudoephedrine.Approved
ThalidomidePseudoephedrine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Theobromine.Approved, Investigational
TheodrenalineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Theodrenaline.Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pseudoephedrine.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Pseudoephedrine.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Pseudoephedrine.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Thiopropazate.Experimental
ThioproperazineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Thioproperazine.Approved
ThioridazineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Thiothixene.Approved
ThonzylaminePseudoephedrine may decrease the sedative and stimulatory activities of Thonzylamine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Pseudoephedrine.Approved, Investigational
TianeptineTianeptine may increase the vasopressor activities of Pseudoephedrine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Tiapride.Approved, Investigational
TigecyclineThe risk or severity of adverse effects can be increased when Tigecycline is combined with Pseudoephedrine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Pseudoephedrine.Vet Approved
TilidinePseudoephedrine may increase the analgesic activities of Tilidine.Experimental
TimololThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pseudoephedrine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Tobramycin is combined with Pseudoephedrine.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Tofisopam is combined with Pseudoephedrine.Approved
TolazolineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pseudoephedrine.Approved, Withdrawn
ToloxatoneToloxatone may increase the hypertensive activities of Pseudoephedrine.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Tolperisone is combined with Pseudoephedrine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Pseudoephedrine.Approved
TramadolPseudoephedrine may increase the analgesic activities of Tramadol.Approved, Investigational
TramazolineThe risk or severity of adverse effects can be increased when Tramazoline is combined with Pseudoephedrine.Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Tramiprosate is combined with Pseudoephedrine.Investigational
TranylcypromineTranylcypromine may increase the hypertensive activities of Pseudoephedrine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Trazodone.Approved, Investigational
TretoquinolThe risk or severity of adverse effects can be increased when Tretoquinol is combined with Pseudoephedrine.Experimental
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Pseudoephedrine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Pseudoephedrine.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Pseudoephedrine.Approved
TriclofosThe risk or severity of adverse effects can be increased when Triclofos is combined with Pseudoephedrine.Withdrawn
TrifluoperazineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Triflupromazine.Approved, Vet Approved
TrimazosinThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Trimazosin.Experimental
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Pseudoephedrine.Approved
TrimipramineTrimipramine may increase the vasopressor activities of Pseudoephedrine.Approved
TripelennaminePseudoephedrine may decrease the sedative and stimulatory activities of Tripelennamine.Approved, Vet Approved
TriprolidinePseudoephedrine may decrease the sedative and stimulatory activities of Triprolidine.Approved
TritoqualinePseudoephedrine may decrease the sedative and stimulatory activities of Tritoqualine.Approved
TropisetronThe risk or severity of adverse effects can be increased when Tropisetron is combined with Pseudoephedrine.Approved, Investigational
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pseudoephedrine.Approved
TyramineThe risk or severity of adverse effects can be increased when Tyramine is combined with Pseudoephedrine.Investigational, Nutraceutical
UrapidilThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Urapidil.Investigational
Uric AcidThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Uric Acid.Experimental, Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Vabicaserin is combined with Pseudoephedrine.Investigational
ValaciclovirThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Valaciclovir.Approved, Investigational
ValerianThe risk or severity of adverse effects can be increased when Valerian is combined with Pseudoephedrine.Approved, Experimental, Investigational
ValganciclovirThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Valganciclovir.Approved, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Valnoctamide is combined with Pseudoephedrine.Investigational
ValomaciclovirThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Valomaciclovir.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pseudoephedrine.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Valpromide is combined with Pseudoephedrine.Experimental
VenlafaxineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Veralipride.Experimental
VerapamilThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Pseudoephedrine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Pseudoephedrine.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Viloxazine is combined with Pseudoephedrine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Vinbarbital is combined with Pseudoephedrine.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Pseudoephedrine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Pseudoephedrine.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Vinylbital is combined with Pseudoephedrine.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pseudoephedrine.Approved, Investigational
WIN 55212-2The risk or severity of Tachycardia can be increased when WIN 55212-2 is combined with Pseudoephedrine.Experimental
WortmanninThe risk or severity of adverse effects can be increased when Wortmannin is combined with Pseudoephedrine.Experimental
XanthineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Xanthine.Experimental
XP19986The risk or severity of adverse effects can be increased when XP19986 is combined with Pseudoephedrine.Investigational
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Pseudoephedrine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when YKP-1358 is combined with Pseudoephedrine.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Yohimbine is combined with Pseudoephedrine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pseudoephedrine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Pseudoephedrine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Zimelidine.Withdrawn
ZiprasidonePseudoephedrine may decrease the sedative and stimulatory activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Pseudoephedrine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pseudoephedrine.Approved, Investigational
ZolpidemPseudoephedrine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pseudoephedrine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Pseudoephedrine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolPseudoephedrine may decrease the sedative and stimulatory activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Andrew G. Myers, "Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary." U.S. Patent US5760237, issued June, 1991.

US5760237
General References
Not Available
External Links
Human Metabolome Database
HMDB0001943
KEGG Drug
D08449
KEGG Compound
C02765
PubChem Compound
7028
PubChem Substance
46508190
ChemSpider
6761
ChEBI
51209
ChEMBL
CHEMBL1590
Therapeutic Targets Database
DAP000195
PharmGKB
PA451170
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Pseudoephedrine
ATC Codes
R01BA02 — PseudoephedrineR01BA52 — Pseudoephedrine, combinations
AHFS Codes
  • 12:12.12 — Alpha-and Beta-adrenergic Agonists
  • 12:12.00 — Sympathomimetic (Adrenergic) Agents
MSDS
Download (52.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingOtherMultiple System Atrophy (MSA) / Shy-Drager Syndrome1
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedDiagnosticBMI >30 kg/m2 / High Blood Pressure (Hypertension) / Progressive autonomic failure / Shy-Drager Syndrome1
1CompletedTreatmentHealthy Volunteers5
2CompletedTreatmentAllergic Rhinitis (AR)3
2CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
2Unknown StatusTreatmentRhinitis, Seasonal, Allergic1
2WithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections / Sinusitis1
3CompletedTreatmentNasal Congestion Associated With the Common Cold1
3CompletedTreatmentNasal Congestion and Inflammations / Rhinitis1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
3CompletedTreatmentAcute Rhinitis / Pharyngitis1
3CompletedTreatmentRhinitis, Allergic, Perennial1
3CompletedTreatmentRhinitis, Allergic, Seasonal1
3CompletedTreatmentRhinitis / Sleep1
3CompletedTreatmentSeasonal Rhinitis1
3CompletedTreatmentVasomotor Rhinitis1
3CompletedTreatmentAcute Rhinitis1
3Unknown StatusTreatmentViral Infections of the Upper Respiratory Tract1
3WithdrawnTreatmentCoughing / Inflammatory Reaction / Rhinitis1
4CompletedPreventionAcute Upper Respiratory Track Infection1
4CompletedTreatmentAcute Rhinosinusitis / Respiratory Infections, Acute1
4CompletedTreatmentAcute maxillary sinusitis caused by M. catarrhalis / Bronchitis / Respiratory Infections, Acute1
4CompletedTreatmentAcute Rhinitis / Headaches / Nasal Stuffiness1
4CompletedTreatmentNasal Stuffiness1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableSeasonal Allergic Rhinitis (SAR) / Sinusitis1
Not AvailableCompletedBasic ScienceUrethral Sphincter Activity1
Not AvailableCompletedTreatmentAtopics / Rhinitis1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Sinusitis1
Not AvailableCompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
Not AvailableRecruitingBasic ScienceMiddle Ear Disease / Nasal Allergies1
Not AvailableUnknown StatusTreatmentCoughing1

Pharmacoeconomics

Manufacturers
  • Ucb inc
  • Schering plough healthcare products inc
Packagers
  • Actavis Group
  • AG Marin Pharmaceuticals
  • Alaven Pharmaceutical
  • Allaire Pharmaceuticals
  • Allegis Pharmaceuticals
  • Alphagen Laboratories Inc.
  • Ambi Pharmaceuticals Inc.
  • Amend
  • Anip Acquisition Co.
  • Apotheca Inc.
  • Aristos Pharmaceuticals
  • A-S Medication Solutions LLC
  • Athlon Pharmaceuticals Inc.
  • Atlantic Biologicals Corporation
  • Atley Pharmaceuticals
  • Auriga Pharmaceuticals LLC
  • Ballay Pharmaceuticals
  • Banner Pharmacaps Inc.
  • Bayer Healthcare
  • Bergen Brunswig
  • Bio Pharm Inc.
  • Blansett Pharmacal Co. Inc.
  • Boca Pharmacal
  • Bradley Pharmaceuticals Inc.
  • Breckenridge Pharmaceuticals
  • Bryant Ranch Prepack
  • BTA Pharmaceuticals
  • Burel Pharmaceuticals Inc.
  • C.O. Truxton Inc.
  • Capellon Pharmaceuticals LLC
  • Cardinal Health
  • Caremark LLC
  • Carwin Associates Inc.
  • Centrix Pharmaceuticals
  • Centurion Labs
  • Century Pharmaceuticals Inc.
  • Contract Pharm
  • Cornerstone Pharmacy
  • CVS Pharmacy
  • Cypress Pharmaceutical Inc.
  • Dartmouth Pharmaceuticals Inc.
  • Dayton Pharmaceuticals
  • Deliz Pharmaceutical Corp.
  • Deltex Pharmaceuticals Inc.
  • Denison Pharmaceuticals Inc.
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • DSC Laboratories
  • DSM Corp.
  • Dunhall Pharmaceuticals Inc.
  • Duramed
  • Econolab Inc.
  • ECR Pharmaceuticals
  • Elite Laboratories Inc.
  • Emrex Economed Pharmaceuticals Inc.
  • Eon Labs
  • Ethex Corp.
  • Everett Laboratories Inc.
  • Gil Pharmaceutical Corp.
  • Gm Pharmaceuticals Inc.
  • Great Southern Laboratories
  • H.J. Harkins Co. Inc.
  • Hawthorn Pharmaceuticals
  • Health Care Products
  • Heartland Repack Services LLC
  • Hi Tech Pharmacal Co. Inc.
  • Huckaby Pharmaceuticals Inc.
  • International Ethical Labs Inc.
  • Iopharm Laboratories Inc.
  • Irisys Inc.
  • Ivax Pharmaceuticals
  • Jaymac Pharmaceuticals LLC
  • Kaiser Foundation Hospital
  • Kowa Pharmaceuticals America Inc.
  • Kroger Co.
  • KV Pharmaceutical Co.
  • Lake Erie Medical and Surgical Supply
  • Lark Pharmaceuticals Inc.
  • Larken Laboratories Inc.
  • Laser Pharmaceuticals
  • Liberty Pharmaceuticals
  • Llorens Pharmaceutical
  • Macoven Pharmaceuticals LLC
  • Major Pharmaceuticals
  • Marnel Pharmaceuticals Inc.
  • Mckesson Corp.
  • McNeil Laboratories
  • MCR American Pharmaceuticals Inc.
  • Med Tek Pharmaceuticals Inc.
  • Meda AB
  • Medicine Shop
  • Merrell Pharmaceuticals Inc.
  • Midland Pharmaceutical LLC
  • Midlothian Labs
  • Murfreesboro Pharmaceutical Nursing Supply
  • Neilgen Pharma Inc.
  • Nexgen Pharma Inc.
  • Norega Laboratories Inc.
  • Nucare Pharmaceuticals Inc.
  • Numark Laboratories Inc.
  • Pa Benjamin Manufacturing Co. Ltd.
  • Palmetto Pharmaceuticals Inc.
  • Pamlab LLC
  • Patheon Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pell Tech Health Care Private Limited
  • Perrigo Co.
  • Pfizer Inc.
  • Pharma Medica Research Inc.
  • Pharmaceutical Generic Developers Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Poly Pharmaceuticals Inc.
  • Prasco Labs
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Propharma Inc.
  • Provident Pharmaceuticals LLC
  • Qualitest
  • Reckitt Benckiser Inc.
  • Redpharm Drug
  • Remedy Repack
  • Respa Pharmaceuticals Inc.
  • Rij Pharmaceutical Corp.
  • River's Edge Pharmaceuticals
  • Roxane Labs
  • Rx Formulations Corp.
  • S&P Healthcare
  • Sage Pharmaceuticals Inc.
  • Sanofi-Aventis Inc.
  • Schering Corp.
  • Schering-Plough Inc.
  • Schwarz Pharma Inc.
  • Sciele Pharma Inc.
  • Scientific Laboratories Inc.
  • SDA Laboratories Inc.
  • Seatrace Pharmaceuticals Inc.
  • Seneca Pharmaceuticals Inc.
  • Seyer Pharmatec Inc.
  • Silarx Pharmaceuticals
  • SJ Pharmaceuticals LLC
  • Southwood Pharmaceuticals
  • Sovereign Pharmaceuticals Ltd.
  • Stat Rx Usa
  • Stewart Jackson Pharmacal Inc.
  • Taro Pharmaceuticals USA
  • Teamm Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • TG United Inc.
  • Tiber Pharmaceuticals LLC
  • Time-Cap Labs
  • Tri Med Laboratories Inc.
  • Trigen Laboratories Inc.
  • Tya Pharmaceuticals
  • UCB Pharma
  • United Research Laboratories Inc.
  • UPM Pharmaceuticals Inc.
  • US Pharmaceutical Group
  • Varsity Laboratories
  • Verum Pharmaceuticals Inc.
  • Vintage Pharmaceuticals Inc.
  • Vision Pharma LLC
  • Walgreen Co.
  • Warner Lambert Company LLC
  • Watson Pharmaceuticals
  • Winthrop Us
  • Wockhardt Ltd.
  • Wyeth Pharmaceuticals
  • Zyber Pharmaceuticals
Dosage forms
FormRouteStrength
CapsuleOral
Capsule, liquid filledOral
SyrupOral7.5 mg
SolutionOral15 mg/5mL
LiquidOral15 mg/5mL
Tablet, multilayer, extended releaseOral
Capsule; kitOral
Kit; tabletOral
TabletOral30 mg
Capsule, extended releaseOral120 mg
PillOral30 mg/1
Kit; powder, for solutionOral
SyrupOral
Tablet; tablet, extended releaseOral
Tablet, extended releaseOral120 mg
LiquidOral60 mg/60mL
Kit; powderOral
SuspensionOral
Tablet, extended releaseOral
PowderOral
SolutionOral
Tablet, sugar coatedOral
Tablet, coatedOral
Tablet, chewableOral
Tablet, film coated, extended releaseOral
TabletOral120 mg
Capsule, extended releaseOral240 mg
Capsule, gelatin coatedOral30 mg/1
Tablet, sugar coatedOral30 mg/1
Tablet, film coatedOral30 mg/1
LiquidOral
Capsule, extended releaseOral
Tablet, coatedOral30 mg/1
Tablet, extended releaseOral120 mg/1
Tablet, film coatedOral120 mg/1
TabletOral30 mg/1
TabletOral60 mg/1
TabletOral
TabletOral60 mg
ElixirOral
Tablet, multilayerOral
LiquidOral30 mg/5mL
Tablet, extended releaseOral240 mg/1
TabletOral15 mg
SyrupOral30 mg
Tablet, film coatedOral60 mg/1
Powder, for solutionOral
LiquidOral30 mg
LiquidOral7.5 mg
Solution / dropsOral
Tablet, film coatedOral
Tablet, film coated, extended releaseOral120 mg/1
Prices
Unit descriptionCostUnit
Sudafed 24 hour tablet0.84USD tablet
Pseudoephedrine hcl crystal0.67USD g
Afrin 0.05% nose spray0.62USD ml
Sudafed 12 hr sinus-pain caplet0.53USD caplet
Drixoral cold & allergy tablet sa0.4USD tablet
Sudafed om sinus nasal spray0.4USD ml
Afrin no drip sinus pump mist0.38USD ml
Sudafed pe cold & cough caplet0.34USD caplet
Afrin sinus spray0.33USD ml
Chlor-trimeton allergy0.31USD each
Sudafed pe severe cold caplet0.28USD caplet
Guaifenesin-phenylephrine tablet0.27USD tablet
Dimetapp cold-allergy tablet chew0.25USD tablet
Sudafed pe 10 mg tablet0.25USD tablet
Chlor-trimeton 8 mg repetab0.24USD tablet
Sudafed pe day & night tablet0.24USD tablet
Sudafed triple action caplet0.23USD caplet
Sudafed pe nighttime cold caplet0.22USD caplet
Sudafed non-drying sinus caplet0.2USD caplet
Sudafed pe sinus & allergy tablet0.2USD tablet
Sudafed pe sinus headache caplet0.2USD caplet
Sudafed 30 mg tablet0.19USD tablet
Wal-phed 30 mg tablet0.17USD tablet
Suphedrin 30 mg tablet0.15USD tablet
CVS Pharmacy decongestant 30 mg tablet0.12USD tablet
Sudogest 60 mg tablet0.12USD tablet
Medi-phedrine 30 mg tablet0.1USD tablet
Nasal decongestant 30 mg tablet0.1USD tablet
Genaphed plus tablet0.09USD tablet
CVS Pharmacy nasal decongest 30 mg tablet0.07USD tablet
Genaphed 30 mg tablet0.07USD tablet
Pseudoephedrine gg syrup0.07USD ml
Pseudoephedrine 60 mg tablet0.06USD tablet
Children's sudafed pe liquid0.05USD ml
Pseudoephedrine 30 mg tablet0.05USD tablet
Dimetapp cold & cough liquid0.04USD ml
Dimetapp dm cold & cough elix0.04USD ml
Dimetapp long-acting cough liquid0.04USD ml
Suphedrine 30 mg tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6037353Yes1997-09-142017-09-14Us
US6039974No1998-07-312018-07-31Us
US6211246No1999-06-102019-06-10Us
US6469009No1999-07-132019-07-13Us
US7226614No2002-06-102022-06-10Us
US6489329No1996-04-082016-04-08Us
US7014867No2002-06-102022-06-10Us
US6100274Yes2000-01-072020-01-07Us
US6372252No2000-04-282020-04-28Us
US6955821No2000-04-282020-04-28Us
US7838032No2000-04-282020-04-28Us
US7618649Yes2001-06-192021-06-19Us
US6709676No2001-02-182021-02-18Us
US8187630No2000-12-192020-12-19Us
US7863287No2007-02-282027-02-28Us
US6979463No2002-03-282022-03-28Us
US7820199Yes2002-09-282022-09-28Us
US6613357No2000-12-252020-12-25Us
USRE39069No1998-05-292018-05-29Us
US6113942Yes1995-08-282015-08-28Us
US5855912Yes1995-08-282015-08-28Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)119 °CPhysProp
water solubility7 mg/LNot Available
logP0.89KRIL,MB & FUNG,HL (1990)
pKa10.3 (at 0 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility8.26 mg/mLALOGPS
logP1ALOGPS
logP1.32ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)13.89ChemAxon
pKa (Strongest Basic)9.52ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area32.26 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity49.69 m3·mol-1ChemAxon
Polarizability18.83 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9645
Blood Brain Barrier+0.5638
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.7182
P-glycoprotein inhibitor INon-inhibitor0.9795
P-glycoprotein inhibitor IINon-inhibitor0.984
Renal organic cation transporterNon-inhibitor0.8965
CYP450 2C9 substrateNon-substrate0.8001
CYP450 2D6 substrateNon-substrate0.7839
CYP450 3A4 substrateNon-substrate0.7235
CYP450 1A2 substrateNon-inhibitor0.5595
CYP450 2C9 inhibitorNon-inhibitor0.7209
CYP450 2D6 inhibitorInhibitor0.5846
CYP450 2C19 inhibitorNon-inhibitor0.5737
CYP450 3A4 inhibitorNon-inhibitor0.9431
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.907
Ames testNon AMES toxic0.9517
CarcinogenicityNon-carcinogens0.7739
BiodegradationNot ready biodegradable0.7807
Rat acute toxicity2.3882 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9329
hERG inhibition (predictor II)Non-inhibitor0.9277
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.24 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0a4i-9000000000-8f0484f72b48017f1f2e
MS/MS Spectrum - Quattro_QQQ 10V, N/A (Annotated)LC-MS/MSsplash10-016s-3900000000-868bf4bba93d8b4be696
MS/MS Spectrum - Quattro_QQQ 25V, N/A (Annotated)LC-MS/MSsplash10-0159-2900000000-6c55fc67b7576cb42a8a
MS/MS Spectrum - Quattro_QQQ 40V, N/A (Annotated)LC-MS/MSsplash10-0006-9700000000-459686cbaf7d3b59c202
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylpropanes
Direct Parent
Phenylpropanes
Alternative Parents
Aralkylamines / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
Substituents
Phenylpropane / Aralkylamine / 1,2-aminoalcohol / Secondary alcohol / Secondary aliphatic amine / Secondary amine / Alcohol / Organopnictogen compound / Organic oxygen compound / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
secondary alcohol, secondary amine (CHEBI:51209) / Phenylalanine derived alkaloids (C02765)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Wee S, Ordway GA, Woolverton WL: Reinforcing effect of pseudoephedrine isomers and the mechanism of action. Eur J Pharmacol. 2004 Jun 16;493(1-3):117-25. [PubMed:15189772]
  2. Foley KF, Van Dort ME, Sievert MK, Ruoho AE, Cozzi NV: Stereospecific inhibition of monoamine uptake transporters by meta-hydroxyephedrine isomers. J Neural Transm (Vienna). 2002 Oct;109(10):1229-40. [PubMed:12373557]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Wee S, Ordway GA, Woolverton WL: Reinforcing effect of pseudoephedrine isomers and the mechanism of action. Eur J Pharmacol. 2004 Jun 16;493(1-3):117-25. [PubMed:15189772]
  2. Foley KF, Van Dort ME, Sievert MK, Ruoho AE, Cozzi NV: Stereospecific inhibition of monoamine uptake transporters by meta-hydroxyephedrine isomers. J Neural Transm (Vienna). 2002 Oct;109(10):1229-40. [PubMed:12373557]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Wellington K, Jarvis B: Cetirizine/pseudoephedrine. Drugs. 2001;61(15):2231-40; discussion 2241-2. [PubMed:11772135]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Wee S, Ordway GA, Woolverton WL: Reinforcing effect of pseudoephedrine isomers and the mechanism of action. Eur J Pharmacol. 2004 Jun 16;493(1-3):117-25. [PubMed:15189772]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Partial agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Vansal SS, Feller DR: Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. Biochem Pharmacol. 1999 Sep 1;58(5):807-10. [PubMed:10449190]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
Partial agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Vansal SS, Feller DR: Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. Biochem Pharmacol. 1999 Sep 1;58(5):807-10. [PubMed:10449190]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transcriptional activator activity, rna polymerase ii distal enhancer sequence-specific binding
Specific Function
Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2 or IL-4 gene transcription. Also controls gene expression in embryonic cardiac cells. ...
Gene Name
NFATC1
Uniprot ID
O95644
Uniprot Name
Nuclear factor of activated T-cells, cytoplasmic 1
Molecular Weight
101241.73 Da
References
  1. Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Munoz E, Bellido LM: Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012 Feb;34(1):98-106. doi: 10.3109/08923973.2011.582118. Epub 2011 Jun 2. [PubMed:21631396]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Tumor necrosis factor receptor binding
Specific Function
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct ac...
Gene Name
TNF
Uniprot ID
P01375
Uniprot Name
Tumor necrosis factor
Molecular Weight
25644.15 Da
References
  1. Wu Z, Kong X, Zhang T, Ye J, Fang Z, Yang X: Pseudoephedrine/ephedrine shows potent anti-inflammatory activity against TNF-alpha-mediated acute liver failure induced by lipopolysaccharide/D-galactosamine. Eur J Pharmacol. 2014 Feb 5;724:112-21. doi: 10.1016/j.ejphar.2013.11.032. Epub 2013 Dec 21. [PubMed:24365491]
  2. Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Munoz E, Bellido LM: Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012 Feb;34(1):98-106. doi: 10.3109/08923973.2011.582118. Epub 2011 Jun 2. [PubMed:21631396]
10. Nuclear factor kappa-light-chain-enhancer of activated B cells
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
References
  1. Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Munoz E, Bellido LM: Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012 Feb;34(1):98-106. doi: 10.3109/08923973.2011.582118. Epub 2011 Jun 2. [PubMed:21631396]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transcriptional activator activity, rna polymerase ii transcription regulatory region sequence-specific binding
Specific Function
This protein binds the cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters. Binds to the Tax-responsive element (TRE) of HTLV-I. ...

Components:
References
  1. Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Munoz E, Bellido LM: Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012 Feb;34(1):98-106. doi: 10.3109/08923973.2011.582118. Epub 2011 Jun 2. [PubMed:21631396]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Kinase activator activity
Specific Function
Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimu...
Gene Name
IL2
Uniprot ID
P60568
Uniprot Name
Interleukin-2
Molecular Weight
17627.52 Da
References
  1. Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Munoz E, Bellido LM: Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012 Feb;34(1):98-106. doi: 10.3109/08923973.2011.582118. Epub 2011 Jun 2. [PubMed:21631396]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:45